RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $25
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $24 to $25.
RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $24 to $25.